Skip to content

Self Defining Memories in Women Victims of Intimate Partner Violence.

Self Defining Memories in Women Victims of Intimate Partner Violence: a Pilot Study.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03906487
Acronym
SOI-MEM
Enrollment
80
Registered
2019-04-08
Start date
2020-02-06
Completion date
2021-12-31
Last updated
2020-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Domestic Violence

Keywords

Intimate partner violence, Self defining memories

Brief summary

A recent report by the World Health Organization demonstrated that 30 % of women worldwide have been victims of intimate-partner violence (IPV). IPV is a public health problem thus it seems important to propose relevant care. It is difficult to carry out an effective therapy. Psychological care is based on cognitive abilities but these women have cognitive impairment. Few studies investigated their cognitive dysfunction. Investigators suggest in this study an exploration of the Self Defining Memories (SDM) which can highlight the loss of identity of these women and a new target of therapy.

Detailed description

Intimate partner violence among women is associated to identity problems. Indeed, the victims have a poor self esteem and difficulties to express their own wishes. In this study investigators suggest an analysis of a type of memory, that is known to be essential, to profile an identity functioning: self-defining memories. To date, no study has explored SDM in women with IPV. The characteristics of the SDM in women victims of IPV will be compared to a group of women who has never been diagnosed in this situation. Those memories could be used in therapy. A French adaptation of the questionnaire proposed by Singer & Moffitt (1992) will be used (Berna et al., 2011a, 2011b) for the assessment of SDM. Four elements will be study: specificity, meaning, content, affect. The two groups will have two visits: * the first to verify inclusion criteria and assessed psychotraumatic and depressive symptoms; * the last to characterize the SDM.

Interventions

BEHAVIORALAssessment measures MINI, PCL5 and BDI-II and definition of 5 SDM

This group will have two visits: * the first to verify inclusion criteria and assessed psychotraumatic and depressive symptoms by completing assessment measures called MINI, PCL-5, BDI-II ; * the last to characterize the SDM by defining 5 personal memories

BEHAVIORALAssessment measures MINI and definition of 5 SDM

This group will have two visits: * the first to verify inclusion criteria and assessed psychotraumatic and depressive symptoms by completing MINI questionary; * the last to characterize the SDM by and defining 5 personal memories

Sponsors

University Hospital, Toulouse
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

For all participants: * French mother tongue. * Informed consent. * Affiliated to social security For women who are victims of IPV only: * Having at least two physical aggressions * To meet criterion A of the diagnosis of PTSD according to the Diagnostic and Statistical Manual of Mental Disorders DSM (DSM-5) (evaluated using the Mini International Neuropsychiatric Interview, MINI) For women of the control group only: \- None a victim of IPV

Exclusion criteria

For all participants: * Neurological pathology, brain damage. * History of head trauma with loss of consciousness. * Severe, progressive somatic pathology * Psychotherapy in progress * Taking psychotropic drugs or beta-blockers (because of their potential impact on memory capacity) * Pregnant or lactating women * Under a legal regime for the protection of adults For women who are victims of IPV only: * Antecedent or presence of PTSD other than that related to IPV * History or presence of progressive mental disorders (Axis I DSM-5 - evaluated using Mini International Neuropsychiatric Interview, MINI) For women of the control group only: History or presence of progressive mental disorders including PTSD (Axis I DSM-5 - evaluated using Mini International Neuropsychiatric Interview, MINI)

Design outcomes

Primary

MeasureTime frameDescription
Description of five Self Defining Memories.7 to 10 days after inclusion visitThese memories are declined in four dimensions: specificity, content, meaning and emotional valence. Investigator will get a proportion of memories which are specific, which are negative, positive or neutral, which have an integrative meaning and which are associated to violence for IPV victims. The results of Self Defining Memories will be compared between a group of IPV victims and a control group.

Secondary

MeasureTime frameDescription
Proportions of SDM whose content is associated with discomfort in IPV victims compared to those of control.7 to 10 days after inclusion visit
Proportions of SDM whose emotional valence is associated with a feeling of redemption or contamination in IPV victims compared to those of control.7 to 10 days after inclusion visit
Relationships between the 4 dimensions of SDM and psychotraumatic symptoms in IPV victims.7 to 10 days after inclusion visitThese symptoms will be measured via the Posttraumatic Stress Disorder Checklist (PCL-5 scale).This is a self-questionnaire to assess the main symptoms of Post traumatic stress disorder. It has 20 items that evaluate the intensity and frequency of symptoms in the previous month using scores from 1 to 4.The higher the score, the more important the trauma.
Relationships between the 4 dimensions of SDM and depressive symptoms in IPV victims.7 to 10 days after inclusion visitThese symptoms will be measured via the Beck Depressin Inventory (BDI) scale: this is a self-questionnaire to assess the severity of depressive symptoms using 21 items. Once the test is completed, a score is made by decounting, then compared according to the score, thus determining the severity of the depression: 0 - 9: indicates a minor depression 10 - 18: indicates slight depression 19 - 29: indicates moderate depression 30 - 63: indicates severe depression

Countries

France

Contacts

Primary ContactDamien PIERRE, MD
pierre.dam@chu-toulouse.fr(0)5 34 55 75 68
Backup ContactSophie BILLOUX
sophie.billoux@inserm.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026